<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122846">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02102672</url>
  </required_header>
  <id_info>
    <org_study_id>13-229</org_study_id>
    <nct_id>NCT02102672</nct_id>
  </id_info>
  <brief_title>Trimetazidine in Pulmonary Artery Hypertension</brief_title>
  <official_title>Comprehensive Evaluation of Right Ventricular Function, Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension: Effects of a Fatty Acid Oxidation Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo Nacional de Desarrollo Científico y Tecnológico, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15
      persons per million. Although current therapy has improve disease prognosis, PAH still has a
      poor survival, with a median survival of 2.8 years after diagnosis.  In the last few years
      new key elements in PAH pathogenesis have been discovered, such as the role of metabolism in
      disease onset and progression. In fact, PAH pulmonary  smooth muscle cells switch into a
      glycolytic phenotype which resembles the metabolism of cancer cells. The investigators
      hypothesis is that &quot;fatty acid oxidation inhibition reverts the PAH adverse phenotype by
      restoring mitochondrial function and morphology, decreasing proliferation and restoring
      apoptosis susceptibility in pulmonary smooth muscle cells &quot;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in right ventricular (RV) function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in RV function assessed by echo 3d (strain-strain rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in exercise capacity</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in exercise capacity assessed by 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in symptoms</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Borg dyspnea index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in B-type natriuretic peptide, galectin-3 and rho-kinase activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to first PAH related medical event (ER evaluation, hospitalization or death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pulmonary Artery Hypertension</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 pill bid, 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimetazidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimetazidine 35 mg bid for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <arm_group_label>Trimetazidine</arm_group_label>
    <other_name>Vastarel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAH patients belonging to the following subgroups of the updated Dana Point
             Classification Group 1

               1. Idiopathic PAH

               2. Heritable PAH

               3. Drug or toxin-induced PAH

               4. PAH associated with connective tissue disease

               5. PAH associated to congenital heart disease with simple systemic-to-pulmonary
                  shunt at least 1 year after surgical repair

               6. PAH associated to HIV infection

          -  Documented hemodynamic diagnosis of PAH by right ventricular catheterization
             performed any time prior to screening

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients belonging to the subgroups of the updated Dana Point Classification Group I
             not listed in the inclusion criteria

          -  Patients belonging to the groups 2-5 of the updated Dana Point Classification Group

          -  Moderate to severe chronic pulmonary obstructive disease

          -  Documented left ventricular dysfunction

          -  Severe renal impairment (Serum creatinine &gt; 2.5 mg/dL)

          -  Patients who are receiving or have been receiving any investigational drugs within 1
             month before the baseline visit

          -  Acute or chronic impairment (other than dyspnea) limiting the ability to comply with
             study requirements

          -  Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with study requirements

          -  Life expectancy less than 12 months

          -  Females who are lactating or pregnant or those who plan to become pregnant during the
             study

          -  Known hypersensitivity to any of the excipients of the drug formulation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo F Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo F Castro, MD</last_name>
    <phone>+56223543334</phone>
    <email>pcastro@med.puc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugo E Verdejo, MD, PhD</last_name>
    <phone>+569223543624</phone>
    <email>hverdejo@med.puc.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana A Llevaneras, RN</last_name>
      <phone>+56223548236</phone>
      <email>sllevane@med.puc.cl</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
